Novartis Consumer Health

Wimblehurst Road, Horsham, West Sussex, RH12 5AB
Telephone: +44 (0)1403 210 211
Fax: +44 (0)1403 323 919
Medical Information Direct Line: +44 (0)1403 323 046
Medical Information e-mail: medicalaffairs.uk@novartis.com
Customer Care direct line: +44 (0)1403 218 111
Medical Information Fax: +44 (0)1403 324 024
Summary of Product Characteristics last updated on the eMC: 08/02/2010
SPC Otrivine Adult Nasal Drops

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 08/02/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   22-Dec-2009
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 5.1

Addition of paragraph:

In a double-blind, saline solution (Otrisal) controlled study in patients with common cold, the decongestant effect of Otrivine was significantly superior (p<0.0001) to Otrisal saline solution based on rhinomanometry measurement at 1 hour after administration of the study drugs.

 

 

Section 10

Date change from 14 October 2003 to 22 December 2009

Updated on 31/10/2007 and displayed until 08/02/2010
Reasons for adding or updating:
  • Change to separate SPCs covering individual presentations
Date of revision of text on the SPC:   10/2003
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change to separate SPCs covering individual presentations
Updated on 19/09/2002 and displayed until 31/10/2007
Reasons for adding or updating:
  • Change to section 6.1 - List of Excipients
  • Change to section 6. 3 - Shelf Life
Updated on 14/08/2001 and displayed until 19/09/2002
Reasons for adding or updating:
  • Addition of joint SPC covering all presentations

Active Ingredients/Generics

 
   xylometazoline hydrochloride


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk